Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Update

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the recipient of a significant growth in short interest in June. As of June 30th, there was short interest totaling 289,957 shares, a growth of 606.2% from the June 15th total of 41,058 shares. Approximately 8.5% of the company’s stock are sold short. Based on an average daily volume of 18,514,293 shares, the short-interest ratio is currently 0.0 days.

Catheter Precision Stock Down 14.7%

NYSEAMERICAN VTAK traded down $0.12 during trading on Monday, hitting $0.67. 581,092 shares of the company traded hands, compared to its average volume of 3,688,308. Catheter Precision has a 12 month low of $0.61 and a 12 month high of $4.94. The business has a fifty day simple moving average of $0.92 and a 200 day simple moving average of $1.32. The company has a current ratio of 0.06, a quick ratio of 0.06 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $2.43 million, a P/E ratio of -0.05 and a beta of -1.07.

Catheter Precision (NYSEAMERICAN:VTAK) last released its quarterly earnings results on Monday, May 18th. The company reported ($1.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($20.90) by $19.51. Catheter Precision had a negative return on equity of 76.51% and a negative net margin of 1,297.56%.The company had revenue of $0.43 million during the quarter, compared to the consensus estimate of $1.60 million.

Hedge Funds Weigh In On Catheter Precision

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC acquired a new position in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned 2.08% of Catheter Precision at the end of the most recent quarter. 20.34% of the stock is currently owned by hedge funds and other institutional investors.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.